nodes	percent_of_prediction	percent_of_DWPC	metapath
Tenofovir—ABCC10—Vincristine—colon cancer	0.21	0.275	CbGbCtD
Tenofovir—ABCC10—Methotrexate—colon cancer	0.127	0.167	CbGbCtD
Tenofovir—ABCC4—Fluorouracil—colon cancer	0.111	0.145	CbGbCtD
Tenofovir—ABCC2—Irinotecan—colon cancer	0.0688	0.09	CbGbCtD
Tenofovir—ABCC4—Methotrexate—colon cancer	0.0612	0.08	CbGbCtD
Tenofovir—ABCC2—Vincristine—colon cancer	0.0601	0.0786	CbGbCtD
Tenofovir—SLC22A8—Methotrexate—colon cancer	0.0382	0.05	CbGbCtD
Tenofovir—ABCC2—Methotrexate—colon cancer	0.0364	0.0476	CbGbCtD
Tenofovir—SLC22A6—Methotrexate—colon cancer	0.0266	0.0348	CbGbCtD
Tenofovir—CYP1A2—Fluorouracil—colon cancer	0.0246	0.0322	CbGbCtD
Tenofovir—ABCC2—bile—colon cancer	0.00883	0.1	CbGeAlD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—ODC1—colon cancer	0.00409	0.0804	CbGpPWpGaD
Tenofovir—NME2—embryo—colon cancer	0.00399	0.0452	CbGeAlD
Tenofovir—NME1-NME2—liver—colon cancer	0.00337	0.0381	CbGeAlD
Tenofovir—NME2—epithelium—colon cancer	0.00325	0.0369	CbGeAlD
Tenofovir—NME1—renal system—colon cancer	0.0032	0.0363	CbGeAlD
Tenofovir—AK2—bone marrow—colon cancer	0.00316	0.0358	CbGeAlD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—ODC1—colon cancer	0.0031	0.0609	CbGpPWpGaD
Tenofovir—AK4—renal system—colon cancer	0.00309	0.035	CbGeAlD
Tenofovir—AK2—vagina—colon cancer	0.00302	0.0343	CbGeAlD
Tenofovir—NME2—renal system—colon cancer	0.00302	0.0342	CbGeAlD
Tenofovir—NME1—lymphoid tissue—colon cancer	0.00266	0.0302	CbGeAlD
Tenofovir—NME1—digestive system—colon cancer	0.00263	0.0298	CbGeAlD
Tenofovir—NME1-NME2—lymph node—colon cancer	0.00258	0.0292	CbGeAlD
Tenofovir—AK2—liver—colon cancer	0.00255	0.0289	CbGeAlD
Tenofovir—Hepatic steatosis—Capecitabine—colon cancer	0.00255	0.0276	CcSEcCtD
Tenofovir—AK4—digestive system—colon cancer	0.00253	0.0287	CbGeAlD
Tenofovir—NME2—lymphoid tissue—colon cancer	0.00251	0.0284	CbGeAlD
Tenofovir—NME2—digestive system—colon cancer	0.00248	0.0281	CbGeAlD
Tenofovir—NME1—bone marrow—colon cancer	0.00242	0.0275	CbGeAlD
Tenofovir—AK4—vagina—colon cancer	0.00224	0.0253	CbGeAlD
Tenofovir—NME1—liver—colon cancer	0.00196	0.0222	CbGeAlD
Tenofovir—AK2—lymph node—colon cancer	0.00196	0.0222	CbGeAlD
Tenofovir—Adenosine triphosphate—AKT1—colon cancer	0.00191	0.463	CrCbGaD
Tenofovir—AK4—liver—colon cancer	0.00189	0.0214	CbGeAlD
Tenofovir—Adenosine monophosphate—SRC—colon cancer	0.00188	0.456	CrCbGaD
Tenofovir—Serum creatinine increased—Irinotecan—colon cancer	0.00187	0.0203	CcSEcCtD
Tenofovir—NME2—liver—colon cancer	0.00184	0.0209	CbGeAlD
Tenofovir—Hepatomegaly—Irinotecan—colon cancer	0.00163	0.0176	CcSEcCtD
Tenofovir—ABCC2—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00161	0.0317	CbGpPWpGaD
Tenofovir—ABCC10—ABC-family proteins mediated transport—ABCB1—colon cancer	0.00158	0.031	CbGpPWpGaD
Tenofovir—AK2—Nucleotide metabolism—TYMS—colon cancer	0.00155	0.0304	CbGpPWpGaD
Tenofovir—NME1—lymph node—colon cancer	0.0015	0.017	CbGeAlD
Tenofovir—ABCC10—renal system—colon cancer	0.00147	0.0166	CbGeAlD
Tenofovir—AK4—lymph node—colon cancer	0.00145	0.0164	CbGeAlD
Tenofovir—NME2—lymph node—colon cancer	0.00141	0.016	CbGeAlD
Tenofovir—NME1—Regulation of CDC42 activity—APC—colon cancer	0.00128	0.0252	CbGpPWpGaD
Tenofovir—Serum creatinine increased—Capecitabine—colon cancer	0.00125	0.0136	CcSEcCtD
Tenofovir—Bone pain—Vincristine—colon cancer	0.00123	0.0134	CcSEcCtD
Tenofovir—ABCC10—lymphoid tissue—colon cancer	0.00122	0.0138	CbGeAlD
Tenofovir—ABCC4—renal system—colon cancer	0.00122	0.0138	CbGeAlD
Tenofovir—SLC22A8—renal system—colon cancer	0.00121	0.0137	CbGeAlD
Tenofovir—ABCC10—digestive system—colon cancer	0.0012	0.0136	CbGeAlD
Tenofovir—ABCC2—renal system—colon cancer	0.00118	0.0133	CbGeAlD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00113	0.0222	CbGpPWpGaD
Tenofovir—ABCC10—bone marrow—colon cancer	0.00111	0.0126	CbGeAlD
Tenofovir—Hepatomegaly—Capecitabine—colon cancer	0.00109	0.0118	CcSEcCtD
Tenofovir—NME2—Nucleotide metabolism—TYMS—colon cancer	0.00107	0.0211	CbGpPWpGaD
Tenofovir—Urine output increased—Vincristine—colon cancer	0.00107	0.0116	CcSEcCtD
Tenofovir—ABCC10—vagina—colon cancer	0.00106	0.012	CbGeAlD
Tenofovir—ABCC4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.00105	0.0206	CbGpPWpGaD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—BAX—colon cancer	0.00102	0.0201	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CDH1—colon cancer	0.00102	0.02	CbGpPWpGaD
Tenofovir—ABCC4—digestive system—colon cancer	0.000997	0.0113	CbGeAlD
Tenofovir—Multiple fractures—Methotrexate—colon cancer	0.000987	0.0107	CcSEcCtD
Tenofovir—Fracture—Methotrexate—colon cancer	0.000987	0.0107	CcSEcCtD
Tenofovir—Polyuria—Vincristine—colon cancer	0.000977	0.0106	CcSEcCtD
Tenofovir—ABCC2—digestive system—colon cancer	0.000965	0.0109	CbGeAlD
Tenofovir—ABCC4—bone marrow—colon cancer	0.000919	0.0104	CbGeAlD
Tenofovir—Renal failure acute—Irinotecan—colon cancer	0.000905	0.0098	CcSEcCtD
Tenofovir—ABCC10—liver—colon cancer	0.000895	0.0101	CbGeAlD
Tenofovir—AK2—Metabolism—CA7—colon cancer	0.000894	0.0176	CbGpPWpGaD
Tenofovir—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000884	0.0174	CbGpPWpGaD
Tenofovir—Renal impairment—Irinotecan—colon cancer	0.000878	0.00951	CcSEcCtD
Tenofovir—Proteinuria—Capecitabine—colon cancer	0.000877	0.00949	CcSEcCtD
Tenofovir—Protein urine present—Capecitabine—colon cancer	0.000864	0.00936	CcSEcCtD
Tenofovir—CYP1A2—renal system—colon cancer	0.000826	0.00936	CbGeAlD
Tenofovir—NME1—Arf6 trafficking events—CDH1—colon cancer	0.000823	0.0162	CbGpPWpGaD
Tenofovir—NME1—Nucleotide metabolism—TYMS—colon cancer	0.000813	0.016	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CDH1—colon cancer	0.000809	0.0159	CbGpPWpGaD
Tenofovir—Bone pain—Capecitabine—colon cancer	0.000804	0.00871	CcSEcCtD
Tenofovir—Blood creatinine increased—Irinotecan—colon cancer	0.000783	0.00847	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—BAX—colon cancer	0.000775	0.0152	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000769	0.0151	CbGpPWpGaD
Tenofovir—Hypokalaemia—Irinotecan—colon cancer	0.00076	0.00823	CcSEcCtD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CCND1—colon cancer	0.00076	0.0149	CbGpPWpGaD
Tenofovir—Muscular weakness—Vincristine—colon cancer	0.000757	0.00819	CcSEcCtD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—CTNNB1—colon cancer	0.000752	0.0148	CbGpPWpGaD
Tenofovir—ABCC2—Irinotecan Pathway—APC—colon cancer	0.000744	0.0146	CbGpPWpGaD
Tenofovir—ABCC4—liver—colon cancer	0.000743	0.00842	CbGeAlD
Tenofovir—ABCC2—liver—colon cancer	0.000719	0.00815	CbGeAlD
Tenofovir—Nasopharyngitis—Fluorouracil—colon cancer	0.000715	0.00775	CcSEcCtD
Tenofovir—Pancreatitis—Irinotecan—colon cancer	0.000708	0.00767	CcSEcCtD
Tenofovir—Muscular weakness—Fluorouracil—colon cancer	0.000706	0.00764	CcSEcCtD
Tenofovir—Urine output increased—Capecitabine—colon cancer	0.000696	0.00754	CcSEcCtD
Tenofovir—ABCC10—lymph node—colon cancer	0.000686	0.00778	CbGeAlD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—SRC—colon cancer	0.00068	0.0134	CbGpPWpGaD
Tenofovir—CYP1A2—digestive system—colon cancer	0.000677	0.00767	CbGeAlD
Tenofovir—Upper respiratory tract infection—Irinotecan—colon cancer	0.000671	0.00727	CcSEcCtD
Tenofovir—Weight decreased—Vincristine—colon cancer	0.000671	0.00726	CcSEcCtD
Tenofovir—Pneumonia—Vincristine—colon cancer	0.000665	0.0072	CcSEcCtD
Tenofovir—Depression—Vincristine—colon cancer	0.000659	0.00714	CcSEcCtD
Tenofovir—Weight decreased—Irinotecan—colon cancer	0.000653	0.00707	CcSEcCtD
Tenofovir—Proteinuria—Methotrexate—colon cancer	0.000653	0.00707	CcSEcCtD
Tenofovir—Neuropathy peripheral—Vincristine—colon cancer	0.000648	0.00702	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000648	0.0127	CbGpPWpGaD
Tenofovir—Pneumonia—Irinotecan—colon cancer	0.000647	0.00701	CcSEcCtD
Tenofovir—Protein urine present—Methotrexate—colon cancer	0.000644	0.00697	CcSEcCtD
Tenofovir—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000643	0.00696	CcSEcCtD
Tenofovir—Polyuria—Capecitabine—colon cancer	0.000637	0.0069	CcSEcCtD
Tenofovir—Sweating—Vincristine—colon cancer	0.000634	0.00686	CcSEcCtD
Tenofovir—Renal failure—Irinotecan—colon cancer	0.000633	0.00685	CcSEcCtD
Tenofovir—Pneumonia—Fluorouracil—colon cancer	0.00062	0.00672	CcSEcCtD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CASP3—colon cancer	0.00062	0.0122	CbGpPWpGaD
Tenofovir—NME2—Metabolism—CA7—colon cancer	0.00062	0.0122	CbGpPWpGaD
Tenofovir—Sweating—Irinotecan—colon cancer	0.000617	0.00668	CcSEcCtD
Tenofovir—Infestation NOS—Fluorouracil—colon cancer	0.000617	0.00668	CcSEcCtD
Tenofovir—Infestation—Fluorouracil—colon cancer	0.000617	0.00668	CcSEcCtD
Tenofovir—NME1—Arf6 trafficking events—CTNNB1—colon cancer	0.000608	0.0119	CbGpPWpGaD
Tenofovir—Renal failure acute—Capecitabine—colon cancer	0.000606	0.00656	CcSEcCtD
Tenofovir—ABCC4—Fluoropyrimidine Activity—TYMS—colon cancer	0.000605	0.0119	CbGpPWpGaD
Tenofovir—Neuropathy peripheral—Fluorouracil—colon cancer	0.000604	0.00654	CcSEcCtD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—CTNNB1—colon cancer	0.000598	0.0117	CbGpPWpGaD
Tenofovir—Renal impairment—Capecitabine—colon cancer	0.000587	0.00636	CcSEcCtD
Tenofovir—Urinary tract disorder—Vincristine—colon cancer	0.000586	0.00635	CcSEcCtD
Tenofovir—Connective tissue disorder—Vincristine—colon cancer	0.000583	0.00631	CcSEcCtD
Tenofovir—Urethral disorder—Vincristine—colon cancer	0.000582	0.0063	CcSEcCtD
Tenofovir—Sinusitis—Fluorouracil—colon cancer	0.000578	0.00626	CcSEcCtD
Tenofovir—ABCC4—ABC-family proteins mediated transport—ABCB1—colon cancer	0.000575	0.0113	CbGpPWpGaD
Tenofovir—ABCC4—lymph node—colon cancer	0.000569	0.00645	CbGeAlD
Tenofovir—Connective tissue disorder—Irinotecan—colon cancer	0.000568	0.00615	CcSEcCtD
Tenofovir—ABCC2—lymph node—colon cancer	0.000551	0.00625	CbGeAlD
Tenofovir—AK2—Metabolism—CHST5—colon cancer	0.000541	0.0106	CbGpPWpGaD
Tenofovir—AK2—Metabolism—ODC1—colon cancer	0.000541	0.0106	CbGpPWpGaD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—SRC—colon cancer	0.00054	0.0106	CbGpPWpGaD
Tenofovir—Mediastinal disorder—Vincristine—colon cancer	0.000535	0.00579	CcSEcCtD
Tenofovir—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000533	0.0105	CbGpPWpGaD
Tenofovir—Blood creatinine increased—Capecitabine—colon cancer	0.000524	0.00567	CcSEcCtD
Tenofovir—Immune system disorder—Irinotecan—colon cancer	0.000522	0.00565	CcSEcCtD
Tenofovir—Mediastinal disorder—Irinotecan—colon cancer	0.000521	0.00564	CcSEcCtD
Tenofovir—Mental disorder—Vincristine—colon cancer	0.00052	0.00563	CcSEcCtD
Tenofovir—Urine output increased—Methotrexate—colon cancer	0.000518	0.00561	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000518	0.0102	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—PIK3CA—colon cancer	0.000517	0.0102	CbGpPWpGaD
Tenofovir—Hypokalaemia—Capecitabine—colon cancer	0.000509	0.00551	CcSEcCtD
Tenofovir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000507	0.00998	CbGpPWpGaD
Tenofovir—CYP1A2—liver—colon cancer	0.000505	0.00572	CbGeAlD
Tenofovir—Nasopharyngitis—Capecitabine—colon cancer	0.0005	0.00541	CcSEcCtD
Tenofovir—Back pain—Vincristine—colon cancer	0.0005	0.00541	CcSEcCtD
Tenofovir—Flatulence—Irinotecan—colon cancer	0.000496	0.00537	CcSEcCtD
Tenofovir—Muscular weakness—Capecitabine—colon cancer	0.000493	0.00534	CcSEcCtD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—EP300—colon cancer	0.000492	0.00967	CbGpPWpGaD
Tenofovir—Back pain—Irinotecan—colon cancer	0.000487	0.00527	CcSEcCtD
Tenofovir—ABCC2—ABC-family proteins mediated transport—ABCB1—colon cancer	0.000485	0.00953	CbGpPWpGaD
Tenofovir—Polyuria—Methotrexate—colon cancer	0.000474	0.00513	CcSEcCtD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—colon cancer	0.000473	0.00931	CbGpPWpGaD
Tenofovir—NME1—Metabolism—CA7—colon cancer	0.00047	0.00923	CbGpPWpGaD
Tenofovir—Renal failure acute—Methotrexate—colon cancer	0.000451	0.00488	CcSEcCtD
Tenofovir—Upper respiratory tract infection—Capecitabine—colon cancer	0.000449	0.00486	CcSEcCtD
Tenofovir—Myalgia—Vincristine—colon cancer	0.00044	0.00476	CcSEcCtD
Tenofovir—Weight decreased—Capecitabine—colon cancer	0.000437	0.00473	CcSEcCtD
Tenofovir—Hyperglycaemia—Capecitabine—colon cancer	0.000436	0.00472	CcSEcCtD
Tenofovir—Pneumonia—Capecitabine—colon cancer	0.000433	0.00469	CcSEcCtD
Tenofovir—Infestation NOS—Capecitabine—colon cancer	0.000431	0.00467	CcSEcCtD
Tenofovir—Infestation—Capecitabine—colon cancer	0.000431	0.00467	CcSEcCtD
Tenofovir—Depression—Capecitabine—colon cancer	0.00043	0.00465	CcSEcCtD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—MYC—colon cancer	0.000429	0.00843	CbGpPWpGaD
Tenofovir—Renal failure—Capecitabine—colon cancer	0.000424	0.00459	CcSEcCtD
Tenofovir—CYP1A2—Metapathway biotransformation—CHST4—colon cancer	0.000423	0.00832	CbGpPWpGaD
Tenofovir—NME1—E-cadherin signaling in the nascent adherens junction—AKT1—colon cancer	0.000422	0.00831	CbGpPWpGaD
Tenofovir—Neuropathy peripheral—Capecitabine—colon cancer	0.000422	0.00457	CcSEcCtD
Tenofovir—Nervous system disorder—Vincristine—colon cancer	0.000413	0.00448	CcSEcCtD
Tenofovir—Haematuria—Capecitabine—colon cancer	0.000411	0.00445	CcSEcCtD
Tenofovir—Chest pain—Fluorouracil—colon cancer	0.00041	0.00444	CcSEcCtD
Tenofovir—Myalgia—Fluorouracil—colon cancer	0.00041	0.00444	CcSEcCtD
Tenofovir—Hyperhidrosis—Vincristine—colon cancer	0.000408	0.00441	CcSEcCtD
Tenofovir—Hepatobiliary disease—Capecitabine—colon cancer	0.000407	0.00441	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000404	0.00795	CbGpPWpGaD
Tenofovir—Nervous system disorder—Irinotecan—colon cancer	0.000403	0.00436	CcSEcCtD
Tenofovir—Anorexia—Vincristine—colon cancer	0.000402	0.00435	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000397	0.0078	CbGpPWpGaD
Tenofovir—Hyperhidrosis—Irinotecan—colon cancer	0.000397	0.0043	CcSEcCtD
Tenofovir—Anorexia—Irinotecan—colon cancer	0.000391	0.00424	CcSEcCtD
Tenofovir—Hepatitis—Capecitabine—colon cancer	0.000387	0.00419	CcSEcCtD
Tenofovir—Nervous system disorder—Fluorouracil—colon cancer	0.000386	0.00418	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Vincristine—colon cancer	0.000384	0.00416	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000382	0.00752	CbGpPWpGaD
Tenofovir—Urinary tract disorder—Capecitabine—colon cancer	0.000382	0.00414	CcSEcCtD
Tenofovir—Insomnia—Vincristine—colon cancer	0.000381	0.00413	CcSEcCtD
Tenofovir—NME1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—colon cancer	0.00038	0.00747	CbGpPWpGaD
Tenofovir—Connective tissue disorder—Capecitabine—colon cancer	0.00038	0.00412	CcSEcCtD
Tenofovir—Urethral disorder—Capecitabine—colon cancer	0.000379	0.00411	CcSEcCtD
Tenofovir—NME2—Metabolism—CHST5—colon cancer	0.000375	0.00738	CbGpPWpGaD
Tenofovir—NME2—Metabolism—ODC1—colon cancer	0.000375	0.00738	CbGpPWpGaD
Tenofovir—Anorexia—Fluorouracil—colon cancer	0.000375	0.00406	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—EP300—colon cancer	0.000373	0.00733	CbGpPWpGaD
Tenofovir—Insomnia—Irinotecan—colon cancer	0.000371	0.00402	CcSEcCtD
Tenofovir—Decreased appetite—Vincristine—colon cancer	0.000366	0.00397	CcSEcCtD
Tenofovir—Dyspnoea—Irinotecan—colon cancer	0.000366	0.00396	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Vincristine—colon cancer	0.000364	0.00394	CcSEcCtD
Tenofovir—Fatigue—Vincristine—colon cancer	0.000363	0.00394	CcSEcCtD
Tenofovir—Dyspepsia—Irinotecan—colon cancer	0.000361	0.00391	CcSEcCtD
Tenofovir—Pain—Vincristine—colon cancer	0.000361	0.0039	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000358	0.00388	CcSEcCtD
Tenofovir—Decreased appetite—Irinotecan—colon cancer	0.000357	0.00386	CcSEcCtD
Tenofovir—Insomnia—Fluorouracil—colon cancer	0.000356	0.00385	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Irinotecan—colon cancer	0.000354	0.00384	CcSEcCtD
Tenofovir—Fatigue—Irinotecan—colon cancer	0.000354	0.00383	CcSEcCtD
Tenofovir—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000353	0.00694	CbGpPWpGaD
Tenofovir—Pancreatitis—Methotrexate—colon cancer	0.000353	0.00382	CcSEcCtD
Tenofovir—NME2—Validated targets of C-MYC transcriptional activation—TP53—colon cancer	0.000352	0.00692	CbGpPWpGaD
Tenofovir—Pain—Irinotecan—colon cancer	0.000351	0.0038	CcSEcCtD
Tenofovir—Dyspnoea—Fluorouracil—colon cancer	0.000351	0.0038	CcSEcCtD
Tenofovir—Immune system disorder—Capecitabine—colon cancer	0.000349	0.00378	CcSEcCtD
Tenofovir—Mediastinal disorder—Capecitabine—colon cancer	0.000349	0.00377	CcSEcCtD
Tenofovir—Dyspepsia—Fluorouracil—colon cancer	0.000346	0.00375	CcSEcCtD
Tenofovir—Gastrointestinal pain—Vincristine—colon cancer	0.000345	0.00373	CcSEcCtD
Tenofovir—Decreased appetite—Fluorouracil—colon cancer	0.000342	0.0037	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000339	0.00368	CcSEcCtD
Tenofovir—Mental disorder—Capecitabine—colon cancer	0.000339	0.00367	CcSEcCtD
Tenofovir—Malnutrition—Capecitabine—colon cancer	0.000337	0.00365	CcSEcCtD
Tenofovir—Pain—Fluorouracil—colon cancer	0.000336	0.00364	CcSEcCtD
Tenofovir—Gastrointestinal pain—Irinotecan—colon cancer	0.000336	0.00364	CcSEcCtD
Tenofovir—Upper respiratory tract infection—Methotrexate—colon cancer	0.000334	0.00362	CcSEcCtD
Tenofovir—Adenosine triphosphate—ABCB1—colon cancer	0.000333	0.0808	CrCbGaD
Tenofovir—Abdominal pain—Vincristine—colon cancer	0.000333	0.00361	CcSEcCtD
Tenofovir—Body temperature increased—Vincristine—colon cancer	0.000333	0.00361	CcSEcCtD
Tenofovir—Flatulence—Capecitabine—colon cancer	0.000332	0.00359	CcSEcCtD
Tenofovir—Back pain—Capecitabine—colon cancer	0.000326	0.00353	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—MYC—colon cancer	0.000325	0.00639	CbGpPWpGaD
Tenofovir—Body temperature increased—Irinotecan—colon cancer	0.000325	0.00351	CcSEcCtD
Tenofovir—Abdominal pain—Irinotecan—colon cancer	0.000325	0.00351	CcSEcCtD
Tenofovir—Pneumonia—Methotrexate—colon cancer	0.000323	0.00349	CcSEcCtD
Tenofovir—Infestation NOS—Methotrexate—colon cancer	0.000321	0.00347	CcSEcCtD
Tenofovir—Infestation—Methotrexate—colon cancer	0.000321	0.00347	CcSEcCtD
Tenofovir—Depression—Methotrexate—colon cancer	0.00032	0.00346	CcSEcCtD
Tenofovir—Renal failure—Methotrexate—colon cancer	0.000315	0.00341	CcSEcCtD
Tenofovir—Body temperature increased—Fluorouracil—colon cancer	0.000311	0.00337	CcSEcCtD
Tenofovir—Hypersensitivity—Vincristine—colon cancer	0.000311	0.00336	CcSEcCtD
Tenofovir—Sweating—Methotrexate—colon cancer	0.000307	0.00333	CcSEcCtD
Tenofovir—Haematuria—Methotrexate—colon cancer	0.000306	0.00331	CcSEcCtD
Tenofovir—Hepatobiliary disease—Methotrexate—colon cancer	0.000303	0.00328	CcSEcCtD
Tenofovir—Hypersensitivity—Irinotecan—colon cancer	0.000302	0.00328	CcSEcCtD
Tenofovir—Asthenia—Vincristine—colon cancer	0.000302	0.00328	CcSEcCtD
Tenofovir—Asthenia—Irinotecan—colon cancer	0.000295	0.00319	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000291	0.00573	CbGpPWpGaD
Tenofovir—Hypersensitivity—Fluorouracil—colon cancer	0.00029	0.00314	CcSEcCtD
Tenofovir—Diarrhoea—Vincristine—colon cancer	0.000288	0.00312	CcSEcCtD
Tenofovir—Hepatitis—Methotrexate—colon cancer	0.000288	0.00312	CcSEcCtD
Tenofovir—Arthralgia—Capecitabine—colon cancer	0.000287	0.0031	CcSEcCtD
Tenofovir—Chest pain—Capecitabine—colon cancer	0.000287	0.0031	CcSEcCtD
Tenofovir—Myalgia—Capecitabine—colon cancer	0.000287	0.0031	CcSEcCtD
Tenofovir—Anxiety—Capecitabine—colon cancer	0.000286	0.00309	CcSEcCtD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000285	0.00308	CcSEcCtD
Tenofovir—NME1—Metabolism—CHST5—colon cancer	0.000284	0.00559	CbGpPWpGaD
Tenofovir—NME1—Metabolism—ODC1—colon cancer	0.000284	0.00559	CbGpPWpGaD
Tenofovir—Urinary tract disorder—Methotrexate—colon cancer	0.000284	0.00308	CcSEcCtD
Tenofovir—Urethral disorder—Methotrexate—colon cancer	0.000282	0.00306	CcSEcCtD
Tenofovir—Diarrhoea—Irinotecan—colon cancer	0.000281	0.00304	CcSEcCtD
Tenofovir—Dizziness—Vincristine—colon cancer	0.000279	0.00302	CcSEcCtD
Tenofovir—Pruritus—Fluorouracil—colon cancer	0.000278	0.00301	CcSEcCtD
Tenofovir—Dizziness—Irinotecan—colon cancer	0.000271	0.00294	CcSEcCtD
Tenofovir—Nervous system disorder—Capecitabine—colon cancer	0.000269	0.00292	CcSEcCtD
Tenofovir—Diarrhoea—Fluorouracil—colon cancer	0.000269	0.00291	CcSEcCtD
Tenofovir—Vomiting—Vincristine—colon cancer	0.000268	0.0029	CcSEcCtD
Tenofovir—Skin disorder—Capecitabine—colon cancer	0.000267	0.00289	CcSEcCtD
Tenofovir—NME1—Validated targets of C-MYC transcriptional activation—TP53—colon cancer	0.000267	0.00525	CbGpPWpGaD
Tenofovir—Rash—Vincristine—colon cancer	0.000266	0.00288	CcSEcCtD
Tenofovir—Hyperhidrosis—Capecitabine—colon cancer	0.000266	0.00288	CcSEcCtD
Tenofovir—Dermatitis—Vincristine—colon cancer	0.000266	0.00288	CcSEcCtD
Tenofovir—Headache—Vincristine—colon cancer	0.000264	0.00286	CcSEcCtD
Tenofovir—Anorexia—Capecitabine—colon cancer	0.000262	0.00284	CcSEcCtD
Tenofovir—Vomiting—Irinotecan—colon cancer	0.000261	0.00283	CcSEcCtD
Tenofovir—Immune system disorder—Methotrexate—colon cancer	0.00026	0.00282	CcSEcCtD
Tenofovir—Dizziness—Fluorouracil—colon cancer	0.00026	0.00282	CcSEcCtD
Tenofovir—Mediastinal disorder—Methotrexate—colon cancer	0.000259	0.00281	CcSEcCtD
Tenofovir—Rash—Irinotecan—colon cancer	0.000259	0.0028	CcSEcCtD
Tenofovir—Dermatitis—Irinotecan—colon cancer	0.000259	0.0028	CcSEcCtD
Tenofovir—Headache—Irinotecan—colon cancer	0.000257	0.00279	CcSEcCtD
Tenofovir—Mental disorder—Methotrexate—colon cancer	0.000252	0.00273	CcSEcCtD
Tenofovir—Malnutrition—Methotrexate—colon cancer	0.000251	0.00271	CcSEcCtD
Tenofovir—Nausea—Vincristine—colon cancer	0.00025	0.00271	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00025	0.00271	CcSEcCtD
Tenofovir—Vomiting—Fluorouracil—colon cancer	0.00025	0.00271	CcSEcCtD
Tenofovir—Insomnia—Capecitabine—colon cancer	0.000249	0.00269	CcSEcCtD
Tenofovir—Rash—Fluorouracil—colon cancer	0.000248	0.00268	CcSEcCtD
Tenofovir—Dermatitis—Fluorouracil—colon cancer	0.000248	0.00268	CcSEcCtD
Tenofovir—Headache—Fluorouracil—colon cancer	0.000246	0.00267	CcSEcCtD
Tenofovir—Dyspnoea—Capecitabine—colon cancer	0.000245	0.00265	CcSEcCtD
Tenofovir—Nausea—Irinotecan—colon cancer	0.000244	0.00264	CcSEcCtD
Tenofovir—Back pain—Methotrexate—colon cancer	0.000242	0.00263	CcSEcCtD
Tenofovir—Dyspepsia—Capecitabine—colon cancer	0.000242	0.00262	CcSEcCtD
Tenofovir—Decreased appetite—Capecitabine—colon cancer	0.000239	0.00259	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Capecitabine—colon cancer	0.000237	0.00257	CcSEcCtD
Tenofovir—Fatigue—Capecitabine—colon cancer	0.000237	0.00257	CcSEcCtD
Tenofovir—Pain—Capecitabine—colon cancer	0.000235	0.00254	CcSEcCtD
Tenofovir—Nausea—Fluorouracil—colon cancer	0.000234	0.00253	CcSEcCtD
Tenofovir—Gastrointestinal pain—Capecitabine—colon cancer	0.000225	0.00243	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000221	0.00435	CbGpPWpGaD
Tenofovir—Body temperature increased—Capecitabine—colon cancer	0.000217	0.00235	CcSEcCtD
Tenofovir—Abdominal pain—Capecitabine—colon cancer	0.000217	0.00235	CcSEcCtD
Tenofovir—Arthralgia—Methotrexate—colon cancer	0.000213	0.00231	CcSEcCtD
Tenofovir—Chest pain—Methotrexate—colon cancer	0.000213	0.00231	CcSEcCtD
Tenofovir—Myalgia—Methotrexate—colon cancer	0.000213	0.00231	CcSEcCtD
Tenofovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000212	0.00229	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000205	0.00404	CbGpPWpGaD
Tenofovir—Hypersensitivity—Capecitabine—colon cancer	0.000202	0.00219	CcSEcCtD
Tenofovir—ABCC4—Fluoropyrimidine Activity—TP53—colon cancer	0.000201	0.00395	CbGpPWpGaD
Tenofovir—Nervous system disorder—Methotrexate—colon cancer	0.000201	0.00217	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.0002	0.00393	CbGpPWpGaD
Tenofovir—Skin disorder—Methotrexate—colon cancer	0.000199	0.00215	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000198	0.00389	CbGpPWpGaD
Tenofovir—Hyperhidrosis—Methotrexate—colon cancer	0.000198	0.00214	CcSEcCtD
Tenofovir—Asthenia—Capecitabine—colon cancer	0.000197	0.00213	CcSEcCtD
Tenofovir—Anorexia—Methotrexate—colon cancer	0.000195	0.00211	CcSEcCtD
Tenofovir—Pruritus—Capecitabine—colon cancer	0.000194	0.00211	CcSEcCtD
Tenofovir—CYP1A2—Metapathway biotransformation—CHST5—colon cancer	0.000194	0.00382	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000193	0.0038	CbGpPWpGaD
Tenofovir—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.00019	0.00374	CbGpPWpGaD
Tenofovir—Diarrhoea—Capecitabine—colon cancer	0.000188	0.00204	CcSEcCtD
Tenofovir—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000186	0.00202	CcSEcCtD
Tenofovir—Insomnia—Methotrexate—colon cancer	0.000185	0.002	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000184	0.00362	CbGpPWpGaD
Tenofovir—Dyspnoea—Methotrexate—colon cancer	0.000182	0.00197	CcSEcCtD
Tenofovir—Dizziness—Capecitabine—colon cancer	0.000182	0.00197	CcSEcCtD
Tenofovir—Dyspepsia—Methotrexate—colon cancer	0.00018	0.00195	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000179	0.00352	CbGpPWpGaD
Tenofovir—Decreased appetite—Methotrexate—colon cancer	0.000178	0.00193	CcSEcCtD
Tenofovir—Gastrointestinal disorder—Methotrexate—colon cancer	0.000177	0.00191	CcSEcCtD
Tenofovir—Fatigue—Methotrexate—colon cancer	0.000176	0.00191	CcSEcCtD
Tenofovir—Pain—Methotrexate—colon cancer	0.000175	0.00189	CcSEcCtD
Tenofovir—Vomiting—Capecitabine—colon cancer	0.000175	0.00189	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000174	0.00343	CbGpPWpGaD
Tenofovir—Rash—Capecitabine—colon cancer	0.000173	0.00188	CcSEcCtD
Tenofovir—Dermatitis—Capecitabine—colon cancer	0.000173	0.00187	CcSEcCtD
Tenofovir—Headache—Capecitabine—colon cancer	0.000172	0.00186	CcSEcCtD
Tenofovir—Gastrointestinal pain—Methotrexate—colon cancer	0.000167	0.00181	CcSEcCtD
Tenofovir—ABCC10—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000165	0.00324	CbGpPWpGaD
Tenofovir—Nausea—Capecitabine—colon cancer	0.000163	0.00177	CcSEcCtD
Tenofovir—Body temperature increased—Methotrexate—colon cancer	0.000162	0.00175	CcSEcCtD
Tenofovir—Abdominal pain—Methotrexate—colon cancer	0.000162	0.00175	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.00016	0.00315	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.00016	0.00314	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000157	0.00308	CbGpPWpGaD
Tenofovir—Hypersensitivity—Methotrexate—colon cancer	0.000151	0.00163	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000148	0.00291	CbGpPWpGaD
Tenofovir—Asthenia—Methotrexate—colon cancer	0.000147	0.00159	CcSEcCtD
Tenofovir—Pruritus—Methotrexate—colon cancer	0.000145	0.00157	CcSEcCtD
Tenofovir—AK2—Metabolism—ABCB1—colon cancer	0.000143	0.00281	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000141	0.00278	CbGpPWpGaD
Tenofovir—AK2—Metabolism—TYMS—colon cancer	0.000141	0.00276	CbGpPWpGaD
Tenofovir—Diarrhoea—Methotrexate—colon cancer	0.00014	0.00152	CcSEcCtD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000136	0.00268	CbGpPWpGaD
Tenofovir—Dizziness—Methotrexate—colon cancer	0.000135	0.00146	CcSEcCtD
Tenofovir—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000133	0.00261	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000132	0.00259	CbGpPWpGaD
Tenofovir—ABCC4—Platelet degranulation—VEGFA—colon cancer	0.000131	0.00257	CbGpPWpGaD
Tenofovir—Vomiting—Methotrexate—colon cancer	0.00013	0.00141	CcSEcCtD
Tenofovir—Rash—Methotrexate—colon cancer	0.000129	0.0014	CcSEcCtD
Tenofovir—Dermatitis—Methotrexate—colon cancer	0.000129	0.0014	CcSEcCtD
Tenofovir—Headache—Methotrexate—colon cancer	0.000128	0.00139	CcSEcCtD
Tenofovir—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	0.000125	0.00245	CbGpPWpGaD
Tenofovir—Nausea—Methotrexate—colon cancer	0.000122	0.00132	CcSEcCtD
Tenofovir—ABCC4—Platelet degranulation—TGFB1—colon cancer	0.00012	0.00236	CbGpPWpGaD
Tenofovir—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	0.000114	0.00225	CbGpPWpGaD
Tenofovir—NME1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000111	0.00219	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PPARG—colon cancer	9.96e-05	0.00196	CbGpPWpGaD
Tenofovir—NME2—Metabolism—ABCB1—colon cancer	9.92e-05	0.00195	CbGpPWpGaD
Tenofovir—NME2—Metabolism—TYMS—colon cancer	9.74e-05	0.00192	CbGpPWpGaD
Tenofovir—ABCC4—Ectoderm Differentiation—CTNNB1—colon cancer	9.61e-05	0.00189	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	8.19e-05	0.00161	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PTGS2—colon cancer	7.83e-05	0.00154	CbGpPWpGaD
Tenofovir—ABCC4—Ectoderm Differentiation—MYC—colon cancer	7.78e-05	0.00153	CbGpPWpGaD
Tenofovir—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	7.66e-05	0.00151	CbGpPWpGaD
Tenofovir—NME1—Metabolism—ABCB1—colon cancer	7.52e-05	0.00148	CbGpPWpGaD
Tenofovir—ABCC4—NRF2 pathway—TGFB1—colon cancer	7.42e-05	0.00146	CbGpPWpGaD
Tenofovir—NME1—Metabolism—TYMS—colon cancer	7.38e-05	0.00145	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	7.15e-05	0.00141	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PPARG—colon cancer	6.9e-05	0.00136	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	6.81e-05	0.00134	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	6.81e-05	0.00134	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	6.62e-05	0.0013	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	6.62e-05	0.0013	CbGpPWpGaD
Tenofovir—AK2—Metabolism—EP300—colon cancer	6.51e-05	0.00128	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	6.45e-05	0.00127	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	6.37e-05	0.00125	CbGpPWpGaD
Tenofovir—SLC22A8—Transmembrane transport of small molecules—ABCB1—colon cancer	6.27e-05	0.00123	CbGpPWpGaD
Tenofovir—ABCC2—NRF2 pathway—TGFB1—colon cancer	6.26e-05	0.00123	CbGpPWpGaD
Tenofovir—ABCC4—Transmembrane transport of small molecules—ABCB1—colon cancer	6.01e-05	0.00118	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—SRC—colon cancer	5.96e-05	0.00117	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	5.93e-05	0.00117	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	5.92e-05	0.00116	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—VEGFA—colon cancer	5.8e-05	0.00114	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	5.8e-05	0.00114	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	5.8e-05	0.00114	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—CA7—colon cancer	5.56e-05	0.00109	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	5.48e-05	0.00108	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PTGS2—colon cancer	5.43e-05	0.00107	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—TGFB1—colon cancer	5.33e-05	0.00105	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PPARG—colon cancer	5.23e-05	0.00103	CbGpPWpGaD
Tenofovir—SLC22A6—Transmembrane transport of small molecules—ABCB1—colon cancer	5.23e-05	0.00103	CbGpPWpGaD
Tenofovir—ABCC2—Transmembrane transport of small molecules—ABCB1—colon cancer	5.07e-05	0.000996	CbGpPWpGaD
Tenofovir—AK2—Metabolism—PIK3CA—colon cancer	4.82e-05	0.000947	CbGpPWpGaD
Tenofovir—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	4.66e-05	0.000916	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	4.53e-05	0.000891	CbGpPWpGaD
Tenofovir—NME2—Metabolism—EP300—colon cancer	4.51e-05	0.000888	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PTGS2—colon cancer	4.11e-05	0.000809	CbGpPWpGaD
Tenofovir—AK2—Metabolism—AKT1—colon cancer	3.94e-05	0.000774	CbGpPWpGaD
Tenofovir—ABCC4—Platelet activation, signaling and aggregation—AKT1—colon cancer	3.7e-05	0.000728	CbGpPWpGaD
Tenofovir—NME1—Metabolism—EP300—colon cancer	3.42e-05	0.000673	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—ODC1—colon cancer	3.37e-05	0.000663	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—CHST5—colon cancer	3.37e-05	0.000663	CbGpPWpGaD
Tenofovir—NME2—Metabolism—PIK3CA—colon cancer	3.34e-05	0.000657	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—EP300—colon cancer	3.16e-05	0.000621	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—SRC—colon cancer	3.07e-05	0.000604	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—VEGFA—colon cancer	2.99e-05	0.000588	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—NRAS—colon cancer	2.95e-05	0.000581	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—TGFB1—colon cancer	2.75e-05	0.00054	CbGpPWpGaD
Tenofovir—NME2—Metabolism—AKT1—colon cancer	2.73e-05	0.000536	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—KRAS—colon cancer	2.54e-05	0.0005	CbGpPWpGaD
Tenofovir—NME1—Metabolism—PIK3CA—colon cancer	2.53e-05	0.000498	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—PIK3CA—colon cancer	2.34e-05	0.000459	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—TP53—colon cancer	2.26e-05	0.000444	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—HRAS—colon cancer	2.16e-05	0.000425	CbGpPWpGaD
Tenofovir—NME1—Metabolism—AKT1—colon cancer	2.07e-05	0.000406	CbGpPWpGaD
Tenofovir—ABCC4—Hemostasis—AKT1—colon cancer	1.91e-05	0.000375	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.39e-05	0.000273	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.09e-05	0.000215	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.1e-06	0.000179	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—ABCB1—colon cancer	8.91e-06	0.000175	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—TYMS—colon cancer	8.75e-06	0.000172	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.73e-06	0.000132	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PPARG—colon cancer	6.2e-06	0.000122	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PTGS2—colon cancer	4.87e-06	9.58e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—EP300—colon cancer	4.05e-06	7.97e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—PIK3CA—colon cancer	3e-06	5.89e-05	CbGpPWpGaD
Tenofovir—CYP1A2—Metabolism—AKT1—colon cancer	2.45e-06	4.82e-05	CbGpPWpGaD
